Weight medicines and compounded copies
If weight or blood sugar is the reason for the search, ask the person who will assess you—the clinician—to name the product and the condition it would treat. Keep the brand and ingredient beside its form: a tablet, an injection or another way the medicine is supplied. A phrase like “the same ingredient” leaves room for questions about the actual product and the reason for its use.
For tirzepatide, Mounjaro and Zepbound are products approved by the federal drug agency, FDA. Certain semaglutide products (Ozempic, Wegovy) also have approvals, as checked November 3, 2026.
Calling a compounded preparation an approved generic misrepresents its status. FDA’s guidance warns that it may mislead people to describe a compounded medicine as the same thing as an approved product. That guidance was checked November 3, 2026.
As of that date, no approved, marketable generic semaglutide or tirzepatide exists in the United States.
Ask for a plain answer to “What product would the pharmacy actually supply?” Keep that answer with the quote. Do not let a change in product become hidden inside a price comparison. If the name differs across the visit notes and the offer, ask which one is intended.
A local empty shelf does not establish an FDA-listed national shortage.
After a recheck on November 3, 2026, the agency’s update reports neither semaglutide nor tirzepatide on its shortage list. The 503B raw-ingredient list has neither drug on it either. 503B refers to registered facilities making medicines free of living germs.
Federal law checked November 3, 2026 limits regular compounding of copies of drugs already sold. For a pharmacist or physician, an exception can apply to a change made for the patient identified in the prescription. The prescriber must determine that this change creates a significant difference for that patient.
Ask which exact basis a compounded offer relies on. A local stock problem is a question about finding supply. It does not itself establish the federal shortage exception. Keep those answers apart when speaking with a service.
In its policy checked November 3, 2026, FDA says adding vitamin B12 to semaglutide may still leave an essentially copied product when its stated conditions apply.
The Kansas pharmacy board also warns that prefilled or routine checkbox prescriptions may not establish a patient-specific need, in its statement checked November 4, 2026.
Ask the clinician to describe the proposed difference in terms of your own care. Ask what would be recorded and who would make the preparation. A blend name can sound specific while leaving the reason for using it unclear. Repeat the reason back as you understand it. Ask the clinician to correct any gap.
Semaglutide acetate and semaglutide sodium are salt forms, meaning chemically different versions of the ingredient. They differ from the active ingredient in the approved drugs. FDA reports no known lawful basis to compound with those salts, as checked November 3, 2026.
For cagrilintide and retatrutide, FDA says federal law forbids compounding with either ingredient. Neither is a component of an approved drug; this was checked November 3, 2026.
Keep the full chemical name when you ask a pharmacist about the proposal. A shortened label may hide the very distinction you are trying to check. The next useful step is a full cost conversation tied to that same product, with coverage treated as its own question.
If you have already been given a proposal, use its exact wording during the conversation. Ask the clinician to point out what is a product name, what is an ingredient and what is a claim about a result. Keep the reply for later comparison.